This page shows the publications co-authored by Lisa Teot and Holcombe Grier.
Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2018 05 01; 124(9):1973-1981.
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019 03; 109:36-50.
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct; 17(10):1396-1408.
Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2016 Jan; 63(1):54-61.
Myogenic tumors in nevoid Basal cell carcinoma syndrome. J Pediatr Hematol Oncol. 2015 Mar; 37(2):147-9.
Mutations in Hedgehog pathway genes in fetal rhabdomyomas. J Pathol. 2013 Sep; 231(1):44-52.
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol. 2007 May 20; 25(15):2057-62.
Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. J Clin Oncol. 2001 Oct 15; 19(20):4058-64.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.